Hervé Decousus, MD; Isabelle Quéré, MD; Alain Leizorovicz, MD
Potential Conflicts of Interest: None disclosed.
Decousus H., Quéré I., Leizorovicz A.; Risk for Venous Thromboembolism in Patients With Superficial Venous Thrombosis. Ann Intern Med. 2010;153:63. doi: 10.7326/0003-4819-153-1-201007060-00026
Download citation file:
Published: Ann Intern Med. 2010;153(1):63.
In response to Dr. Lauer's questions, we cannot confirm that all centers enrolled consecutive patients into the study. However, this approach was strongly recommended when the study design was explained to them. We believe that the slowness of recruitment reflected practical considerations of the physicians and patients' willingness to participate in the study rather than a lower-than-expected disease frequency.
We agree with Dr. Bachmeyer that SVT is common in patients with Buerger disease (1). However, in western European patients, Buerger disease is relatively rare (1). In the POST (Prospective Observational Superficial Thrombophlebitis) study, very few patients had Buerger disease: Only 2.3% of patients presented with an autoimmune disease, including not only Buerger disease but also other autoimmune diseases, such as Behçet disease and lupus-like syndromes. Therefore, although exposure to tobacco smoke is indeed a key factor in the progression of Buerger disease, its prognostic value was not analyzed.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only